期刊文献+

Progress in Combination Therapy of Malignant Melanoma

下载PDF
导出
摘要 Malignant melanoma(MM)is a kind of highly-invasive and highly-metastatic tumor,which is insensitive to radiochemotherapy.It is also one of the most invasive tumors in skin cancer with limited treatment options.Due to its rapid increase in incidence in recent years and the limitations of monotherapy,it is necessary to use combination therapy.The combination therapy can not only enhance the treatment effect,but also avoid the development of drug resistance as much as possible.This paper focused on the combined therapy of targeted traditional therapies,immunotherapy with radiotherapy and chemotherapy or other traditional therapies,as well as the research status and new developments of these combined therapies.
出处 《Agricultural Biotechnology》 CAS 2020年第6期136-140,共5页 农业生物技术(英文版)
基金 Public Welfare Technology Application Research Program of Zhejiang Province(LGF18H160034,LGD20H300001,2015C37125) 2019 National Undergraduate Innovation Training Program(20190354034) 2018 Zhejiang Science and Technology Innovation Activity Program(Emerging talent Program)(2018R417029) 2018 Jiaxing Key Technology Innovation Team 2018 SRT Key Project of Jiaxing University(85178428)。
  • 相关文献

参考文献2

二级参考文献23

  • 1YANG Q, MODI P, NEWCOMB T, et al. Idelalisib: first-in- class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and folllcular lymphoma [J]. Clin CancerRes, 2015, 21 (7) :1537-1542.
  • 2DAVIES A, GOPAL AK, KAHL BS, et al. Mature response da- ta from a phase 2 study of PI3K-delta inhibitor idelalisib in pa- tients with double ( rituximab and alkylating agent) -refractory in- dolent B-cell non-Hodgkin lymphoma[ J]. Clin Adv Hematol On- col, 2014,12(2 Suppl 6) :8 -9.
  • 3TRAYNOR K. Idelalisib approved for three blood cancers [ J ]. Am J Health Syst Pharm ,2014,71 (17) :1430.
  • 4ROTHSCHILD SI. Ceritinib-a second-generation ALK inhibi- tor overcoming resistance in ALK-rearranged non-small cell lung cancer[J]. TranslLung CancerRes, 2014,3(6) :379 -381.
  • 5KHOZIN S, BLUMENTHAL GM, et al. FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-posi- tire non-small cell lung cancer[J].Clin Cancer Res, 2015, 21 (11): 2436-2439.
  • 6GUHA M. Imbruvica-next big drug in B-cell cancer-approved by FDA[J]. Nat Biotechnol, 2014,32(2) :113-115.
  • 7KIM ES, DHILLON S. Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia[ J ]. Drugs, 2015,75 (7) :769 - 776.
  • 8WANG Y, ZHANG LL, WANG ML, et al. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies [ J]. Clin Pharmaeol Ther, 2015,97 (5) :455 - 468.
  • 9TUCKER H, UMEWENI N, WANG ML, et al. NICE guidanceon dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma[ J]. Lancet Oncol, 2014, 15 ( 13 ) : 1425 - 1426.
  • 10WRIGHT C J, MCCORMACK PL. Trametinib: first global approv- al [ J ]. Drugs, 2013,73 ( 1 1 ) : 1245 - 1254.

共引文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部